The Pharmacy Times® Atopic Dermatitis Resource Center is a comprehensive resource for clinical news and expert insights on treatments for atopic dermatitis.
September 12th 2025
Investigators from the phase 3 COAST 1 trial demonstrated the efficacy and safety of amlitelimab in patients with moderate-to-severe atopic dermatitis.